Skip to main content

Advertisement

SpringerLink
Log in

Predictors of hemoglobin decline in non-metastatic prostate cancer patients on androgen deprivation therapy: a matched cohort study

  • Original Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Purpose

The extent and severity of hemoglobin decline after the initiation of androgen deprivation therapy (ADT) is unclear, and predictors of hemoglobin decline in older men with prostate cancer (PC) are not well-characterized.

Methods

Three cohorts were recruited in this prospective study to evaluate the impact of ADT and other factors on hemoglobin decline. Cohorts included ADT users initiating continuous ADT, PC controls, and healthy controls, matched on age and education. All patients with PC had non-metastatic disease. Univariate and multivariable associations between changes in hemoglobin over 12 months and baseline characteristics were evaluated using linear regression models.

Results

We included 250 men (mean age 69 years). The baseline mean hemoglobin was 141 g/L in ADT users, 144 g/L in PC controls, and 149 g/L in healthy controls (p < 0.001). Over 12 months, the mean hemoglobin level declined in ADT users by 8.9 g/L, compared to 0.56 and 2.03 g/L among PC controls and healthy controls, respectively (p < 0.001). Statistically significant predictors of greater hemoglobin decline included ADT use (p < 0.001), lower activities of daily living score (p < 0.001), higher Charlson comorbidity score (p = 0.02), higher baseline hemoglobin level (p < 0.001), and non-White race (p = 0.04) but not age (p = 0.50).

Conclusions

In men with non-metastatic prostate cancer, ADT was independently associated with a decline in hemoglobin level over 12 months. Other predictors of declining hemoglobin included comorbidity, functional status, baseline hemoglobin level, and race. These findings may help clinicians identify patients starting ADT who would benefit from closer hemoglobin monitoring.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Canadian Cancer Society (2009) Canadian cancer statistics 2009. Canadian Cancer Society, Toronto

    Google Scholar 

  2. Asbell SO, Leon SA, Tester WJ, Brereton HD, Ago CT, Rotman M (1996) Development of anemia and recovery in prostate cancer patients treated with combined androgen blockade and radiotherapy. Prostate 29:243–248

    Article  PubMed  CAS  Google Scholar 

  3. Beer TM, Tangen CM, Bland LB, Hussain M, Goldman BH, DeLoughery TG et al (2006) The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer: a multivariate analysis of Southwest Oncology Group Study 8894. Cancer 107:489–496

    Article  PubMed  CAS  Google Scholar 

  4. Bland JM, Altman DG (1994) Regression towards mean. Bmj 308:1499

    PubMed  CAS  Google Scholar 

  5. Bylow K, Mohile SG, Stadler WM, Dale W (2007) Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer?: a conceptual review. Cancer 110:2604–2613

    Article  PubMed  CAS  Google Scholar 

  6. Chander S, Choo R, Danjoux C, Morton G, Pearse A, Deboer G et al (2005) Effect of androgen suppression on hemoglobin in prostate cancer patients undergoing salvage radiotherapy plus 2-year buserelin acetate for rising PSA after surgery. Int J Radiat Oncol Biol Phys 62:719–724

    Article  PubMed  CAS  Google Scholar 

  7. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 40:373–383

    Article  PubMed  CAS  Google Scholar 

  8. Choo R, Chander S, Danjoux C, Morton G, Pearce A, Deboer G et al (2005) How are hemoglobin levels affected by androgen deprivation in non-metastatic prostate cancer patients? Can J Urol 12:2547–2552

    PubMed  Google Scholar 

  9. den Elzen WP, Willems JM, Westendorp RG, de Craen AJ, Assendelft WJ, Gussekloo J (2009) Effect of anemia and comorbidity on functional status and mortality in old age: results from the Leiden 85-plus Study. Cmaj 181:151–157

    Article  Google Scholar 

  10. Fonseca R, Rajkumar SV, White WL, Tefferi A, Hoagland HC (1998) Anemia after orchiectomy. Am J Hematol 59:230–233

    Article  PubMed  CAS  Google Scholar 

  11. Harrell FE Jr (2001) Multivariable modeling strategies. In: Harrell FE Jr (ed) Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis. Springer, New York, pp 53–86

    Google Scholar 

  12. Hoffman RM, Gilliland FD, Eley JW, Harlan LC, Stephenson RA, Stanford JL et al (2001) Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study. J Natl Cancer Inst 93:388–395

    Article  PubMed  CAS  Google Scholar 

  13. Holzbeierlein JM (2006) Managing complications of androgen deprivation therapy for prostate cancer. Urol Clin North Am 33:181–190, vi

    Article  PubMed  Google Scholar 

  14. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics. CA Cancer J Clin 59:225–249

    Article  PubMed  Google Scholar 

  15. Lawton MP, Brody EM (1969) Assessment of older people: self-maintaining and instrument activities of daily living. Gerontologist 9:179–186

    Article  PubMed  CAS  Google Scholar 

  16. Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS et al (2007) Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 25:1596–1605

    Article  PubMed  CAS  Google Scholar 

  17. Mahoney FI, Barthel DW (1965) Functional evaluation: the Barthel Index. Md State Med J 14:61–65

    PubMed  CAS  Google Scholar 

  18. Maraldi C, Volpato S, Cesari M, Cavalieri M, Onder G, Mangani I et al (2006) Anemia and recovery from disability in activities of daily living in hospitalized older persons. J Am Geriatr Soc 54:632–636

    Article  PubMed  Google Scholar 

  19. Mettlin CJ, Murphy GP, Cunningham MP, Menck HR (1997) The national cancer data base report on race, age, and region variations in prostate cancer treatment. Cancer 80:1261–1266

    Article  PubMed  CAS  Google Scholar 

  20. Nalesnik JG, Mysliwiec AG, Canby-Hagino E (2004) Anemia in men with advanced prostate cancer: incidence, etiology, and treatment. Rev Urol 6:1–4

    PubMed  Google Scholar 

  21. Nishiyama T, Ishizaki F, Anraku T, Shimura H, Takahashi K (2005) The influence of androgen deprivation therapy on metabolism in patients with prostate cancer. J Clin Endocrinol Metab 90:657–660

    Article  PubMed  CAS  Google Scholar 

  22. Rothman KJ (1990) No adjustments are needed for multiple comparisons. Epidemiology 1:43–46

    Article  PubMed  CAS  Google Scholar 

  23. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L et al (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458–1468

    PubMed  CAS  Google Scholar 

  24. Strum SB, McDermed JE, Scholz MC, Johnson H, Tisman G (1997) Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol 79:933–941

    Article  PubMed  CAS  Google Scholar 

  25. Zarychanski R, Houston DS (2008) Anemia of chronic disease: a harmful disorder or an adaptive, beneficial response? Cmaj 179:333–337

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

We are very grateful to all study participants for their contributions to this study and the Canadian Cancer Society for funding this study.

Conflict of interest

None declared

Author information

Authors and Affiliations

  1. Division of General Internal Medicine & Clinical Epidemiology, University Health Network, Room EN 14-214, 200 Elizabeth Street, Toronto, ON, M5G 2C4, Canada

    Narhari Timilshina, Shabbir Hussain, Henriette Breunis & Shabbir M. H. Alibhai

  2. Geriatric Program, Toronto Rehabilitation Institute, Toronto, ON, Canada

    Shabbir M. H. Alibhai

  3. Department of Medicine, University of Toronto, Toronto, ON, Canada

    Shabbir M. H. Alibhai

  4. Department of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada

    Shabbir M. H. Alibhai

Authors
  1. Narhari Timilshina
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shabbir Hussain
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Henriette Breunis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shabbir M. H. Alibhai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shabbir M. H. Alibhai.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Timilshina, N., Hussain, S., Breunis, H. et al. Predictors of hemoglobin decline in non-metastatic prostate cancer patients on androgen deprivation therapy: a matched cohort study. Support Care Cancer 19, 1815–1821 (2011). https://doi.org/10.1007/s00520-010-1023-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-010-1023-6

Keywords

Search

Navigation